Skip to main content

Table 3 Comparison between studies using bevacizumab for central retinal vein occlusion

From: Prospective evaluation of intravitreal bevacizumab for ischemic central retinal vein occlusion

Study

Type of CRVO

Eyes

Baseline visual acuity, logMAR

6 month visual acuity, logMAR

Baseline CFT, μm

6 month CFT, μm

Our study

iCRVO only

9

1.3 (1 to HM)

1.7 (1.3 to NLP)

858 ± 311

243 ± 106

Prigliner et al. [12]

iCRVO only

17

1.52 ± 0.34

1.06 ± 0.45

534 ± 193

279 ± 127

Costa et al. [17]

iCRVO and non-iCRVO

7

1.21 ± 0.36

0.68 ± 0.32

730 ± 257

260 ± 135

  1. CRVO central retinal vein occlusion, iCRVO ischemic central retinal vein occlusion, non-iCRVO non-ischemic central retinal vein occlusion, CFT central foveal thickness